Medigene has said it will cut 40% of its workforce and delay the start of clinical trials of its lead asset as it re-jigs its pipeline of T-cell receptor (TCR) therapies for cancer. For the time ...

Medigene ( (DE:MDG1)) has issued an update. Medigene AG has announced the execution of the first tranche of a Standby Equity ...